U.S. Healthcare CRO Market Projected to Reach $29.68 Billion by 2034, Growing at 7.1% CAGR
The U.S. healthcare contract research organization market is expected to grow from $15.01 billion in 2025 to $29.68 billion by 2034, driven by increasing R&D investments and technological advancements.
Clinical Trial Sites Face Growing Technology Burden as Industry Pushes for Greater Diversity and Efficiency
Clinical trial sites are struggling with technological overload, with 60% of sites managing over 20 overlapping software systems, creating significant administrative burden for investigators.
Mobile Eye Clinic Innovation Streamlines Phase 1 Trial Safety Assessments
Syneos Health successfully integrated 20/20 Onsite's Mobile Clinical Suite to conduct comprehensive eye safety assessments for over 65 patients in a Phase 1 clinical trial.
U.S. Cell and Gene Therapy Bioanalytical Testing Market to Reach $349 Million by 2034
The U.S. cell and gene therapy bioanalytical testing services market is projected to grow from $181.73 million in 2025 to $349.29 million by 2034, representing a CAGR of 7.53%.
Syneos Health Announces Webinar on Healthcare Innovation and Digital Transformation Trends for 2025
Syneos Health is hosting a forward-looking webinar on January 28th exploring emerging healthcare trends, focusing on digital health, biotechnology advances, and personalized medicine solutions.
Clinical Trial Outsourcing Market Set to Reach $91.2 Billion by 2034, Driven by Technology Integration and Strategic Partnerships
The global clinical trial outsourcing market is projected to grow from $43.1 billion in 2025 to $91.2 billion by 2034, representing a robust CAGR of 7.46% as pharmaceutical companies increasingly rely on CROs to streamline research processes.
FDA Clears Phase 2 Trial of Leronlimab for Microsatellite-Stable Colorectal Cancer
The FDA has cleared CytoDyn's phase 2 trial of leronlimab in relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
CytoDyn Receives FDA Clearance for Phase II Oncology Trial of Leronlimab in Colorectal Cancer
CytoDyn has received FDA clearance to begin a Phase II oncology trial evaluating leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.
CytoDyn Receives FDA Clearance for Phase II Oncology Trial of Leronlimab in Colorectal Cancer
CytoDyn has obtained FDA clearance to initiate a Phase II trial evaluating leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.
CytoDyn Receives FDA Clearance for Phase II Trial of Leronlimab in Colorectal Cancer
CytoDyn has obtained FDA clearance to initiate a Phase II oncology trial evaluating leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.